Status:
RECRUITING
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Guardant Health, Inc.
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-90 years
Brief Summary
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
Detailed Description
During evolution of primary tumor, tumor cells can be released into the bloodstream. It has also been shown that circulating cell-free tumor DNA (cfDNA) is released from apoptotic or necrotic tumor ce...
Eligibility Criteria
Inclusion
- All subjects need to sign the informed consent form
- All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively.
- Non-small cell lung cancer have to confirmed pathologically after operation
- Clinical stage I - IIIA by AJCC 7th staging system
Exclusion
- Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer
- Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix with 3 years before enrollment
- Recurrent lung cancer
- Stage IIIB, IV by AJCC 7th staging system
Key Trial Info
Start Date :
August 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT03791034
Start Date
August 28 2017
End Date
December 31 2026
Last Update
May 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06351